- $154.86m
- $175.78m
- $88.50m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.96 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.61 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.11% | ||
| Return on Equity | -316.53% | ||
| Operating Margin | -25.95% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 54.51 | 38.21 | 49.09 | 71.32 | 88.5 | 110.98 | 132.71 | 14.2% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biodesix, Inc. is a diagnostic solutions company. It offers two tests (Nodify Lung tests) that assess the risk of cancer in lung nodules and three tests (IQLung tests) that provide treatment guidance after a lung cancer diagnosis. Nodify CDT and Nodify XL2 tests, marketed as Nodify Lung Nodule Risk Assessment, assess the lung nodule's risk of lung cancer to help identify the appropriate treatment pathway. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. The Nodify XL2 test is a blood-based proteomic test that evaluates the likelihood that a lung nodule is benign to help identify patients that may benefit from surveillance imaging. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests, marketed as part of its IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient’s immune system to help guide treatment decisions.
Directors
- John Patience NEC (73)
- Scott Hutton PRE (49)
- Robin Cowie CFO
- Ryan Siurek CAO (49)
- Kieran O'Kane OTH
- Jon Kayyem DRC (54)
- Jean Franchi IND (54)
- Hany Massarany IND (59)
- Jack Schuler IND (80)
- Matthew Strobeck IND (48)
- Charles Watts IND (78)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- December 23rd, 2005
- Public Since
- October 28th, 2020
- No. of Shareholders
- 228
- No. of Employees
- 334
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 10,108,580
- Address
- 919 West Dillon Road, LOUISVILLE, 80027
- Web
- https://www.biodesix.com/
- Phone
- +1 3026587581
- Auditors
- KPMG LLP
Latest News for BDSX
Upcoming Events for BDSX
Biodesix Inc Annual Shareholders Meeting
Biodesix Inc Annual Shareholders Meeting
Q2 2026 Biodesix Inc Earnings Release
Q3 2026 Biodesix Inc Earnings Release
Similar to BDSX
Airsculpt Technologies
NASDAQ Global Market
Alps
NASDAQ Global Market
Exagen
NASDAQ Global Market
Fulgent Genetics
NASDAQ Global Market
InterCure
NASDAQ Global Market
FAQ
As of Today at 19:36 UTC, shares in Biodesix are trading at $15.32. This share price information is delayed by 15 minutes.
Shares in Biodesix last closed at $15.32 and the price had moved by +120.24% over the past 365 days. In terms of relative price strength the Biodesix share price has outperformed the S&P500 Index by +68.48% over the past year.
The overall consensus recommendation for Biodesix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBiodesix does not currently pay a dividend.
Biodesix does not currently pay a dividend.
Biodesix does not currently pay a dividend.
To buy shares in Biodesix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $15.32, shares in Biodesix had a market capitalisation of $154.86m.
Here are the trading details for Biodesix:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BDSX
Based on an overall assessment of its quality, value and momentum Biodesix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biodesix is $30.50. That is 99.09% above the last closing price of $15.32.
Analysts covering Biodesix currently have a consensus Earnings Per Share (EPS) forecast of -$2.99 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biodesix. Over the past six months, its share price has outperformed the S&P500 Index by +83.01%.
As of the last closing price of $15.32, shares in Biodesix were trading +55.81% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biodesix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biodesix's management team is headed by:
- John Patience - NEC
- Scott Hutton - PRE
- Robin Cowie - CFO
- Ryan Siurek - CAO
- Kieran O'Kane - OTH
- Jon Kayyem - DRC
- Jean Franchi - IND
- Hany Massarany - IND
- Jack Schuler - IND
- Matthew Strobeck - IND
- Charles Watts - IND